LabCorp 2015 Annual Report Download - page 7

Index
LCD’s cardiovascular menu includes core cholesterol tests, expanded lipid profiles, a metabolic syndrome profile and tests for
thrombosis and stroke. LCD also offers complete testing for monitoring disease progression and response to therapy, including the clinical decision
support (CDS) reports available through Litholink.
 LCD offers an extensive menu of tests for hemostasis and thrombosis, including bleeding profiles and screening tests, profiles for
reproductive health, factor analysis, thrombin generation markers, and thrombotic risk evaluation.
 LCD offers cytogenetic, molecular cytogenetic, biochemical and molecular genetic tests. The biochemical genetics offerings
include a variety of prenatal screening options including integrated and sequential prenatal assays and non-invasive prenatal testing (NIPT) for more
sensitive and earlier assessment of risk for multiple fetal chromosomal aneuploidies (e.g., Down syndrome). LCD has expanded its cytogenetics offerings
through the use of whole genome single-nucleotide polymorphism (SNP) microarray technology, which provides enhanced detection of subtle
chromosomal changes associated with the etiology of mental retardation, developmental delay and autism. The molecular genetics services include
multiplex analyses of a variety of disorders, gene sequencing applications for both somatic and germ-line alterations and whole exome sequencing.
Through Integrated Genetics (formerly Genzyme Genetics), LCD provides the most comprehensive genetic test menu in the industry as well as
approximately 140 genetic counselors and six medical geneticists to provide patients and their physicians with analysis, assessment and interpretation of
genetics test results to help optimize patient decisions and outcomes.
LCD is a leading provider of advanced hormone/steroid testing including comprehensive services for the endocrine specialist. LCD has
expanded its menu in esoteric endocrine testing and has launched an initiative to develop steroid testing utilizing mass spectrometry technology. Mass
spectrometry is used for detection of low levels of small molecule steroids including testosterone in women, children and hypogonadal men. LCD
additionally offers endocrine related tests for genetic conditions including congenital adrenal hyperplasia, short stature, thyroid cancer, along with
extensive age and gender-related reference intervals for those tests.
 LCD provides complete HIV testing services including viral load measurements, genotyping and phenotyping and host genetic
factors (e.g., HLA B*5701 test) that are important tools in managing and treating HIV infections. The addition of resistance tests, including
PhenoSense®, PhenoSenseGT®, Trofile®, and GenoSure PRIme complement the existing HIV GenoSure® assay and provide an industry-leading,
comprehensive portfolio of HIV resistance testing services. LCD also provides extensive testing services for HCV infections, including both viral load
determinations and strain genotyping and host genetic factors (e.g., the IL-28B and HCV GenoSure NS3/4A tests). LCD continues to develop molecular
assays for infectious disease.
 LCD offers a comprehensive menu of women's health testing, including NuSwab® high quality convenient STD testing, as well
as liquid-based Pap testing with image-guided cervical cytology for improved cervical cancer detection, and out-of-the-vial Pap testing with options for
human papillomavirus (HPV), chlamydia, and gonorrhea. LCD also offers tests and technologies that span the continuum of care for reproductive health,
including maternal serum screening, prenatal diagnostics, ethnicity carrier screening, testing for causes of infertility or miscarriage and postnatal testing
services.
 LCD provides access to the latest tests in the emerging field of pharmacogenetics. These tests can help physicians understand how a
patient will metabolize certain drugs, allowing them to select the most appropriate therapies or adjust dosing.
 LCD provides forensic identity testing used in connection with criminal proceedings and parentage evaluation services that assist in
determining parentage for child support enforcement proceedings and determining genetic relationships for immigration purposes. Parentage testing
involves the evaluation of immunological and genetic markers in specimens obtained from the child, the mother and the alleged father. LCD also
provides testing services in reconstruction cases, which assist in determining parentage without the presence of the parent in question.
LCD provides testing services for the detection of drug and alcohol abuse for private and government customers. These
testing services are designed to produce forensic quality test results that satisfy the rigorous requirements of regulated and non-regulated workplace drug
testing programs. LCD also provides other analytical testing and a variety of support services.
   Through Litholink, LCD uses a programmatic approach to the comprehensive treatment of chronic diseases, including
kidney disease, cardiovascular disease, metabolic bone disease, diabetes, and offers CDS reports to both physicians and patients. LCD believes these
chronic disease programs represent potential significant savings to the healthcare system by increasing the detection of early-stage diseases and
effectively managing chronic disease conditions.
7